InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
56,754.89
(
-2.65%
)
Post# of 252501
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: DonShimoda post# 151299

Friday, 10/26/2012 4:23:29 PM

Friday, October 26, 2012 4:23:29 PM

Post# of 252501
I don't think you got my point. Both trials were in similar patient population, I agree. But, due to the different mechanism of action, those 40% who didn't get MCyR on ponatinib might be among those 18% who achieved MCyR on Synribo, thus 60% and 18% aren't really overlapping patients. I don't see the two drugs as competitors, by the way.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up